<DOC>
	<DOCNO>NCT01331915</DOCNO>
	<brief_summary>In phase I study , investigator want vaccine THERAVAC® ( inactivate toxin couple melanoma antigen ) patient advance metastatic melanoma disease . The primary objective analyze safety inreasing dos vaccine . The secondary objective document whether vaccine induce tumor regression immunize patient .</brief_summary>
	<brief_title>Safety Toxicity Study Vaccination Advanced Metastatic Melanoma Patients</brief_title>
	<detailed_description>There three treatment cohort inclusion patient govern dose-limiting toxicity previous cohort . - first three patient receive dose 50 µg Theravac® - second cohort three patient receive dose 150 µg Theravac® - third cohort three patient receive dose 250 µg Theravac® eventually total 14 patient complete step high dose . All patient receive four immunization every three week two intradermal site two subcutaneous site .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologically proven cutaneous , uveal mucosal melanoma . 2 . Melanoma must metastatic . The origin primary could cutaneous , uveal mucosal metastatic stage accept , except brain leptomeningeal localization present , plasma LDH elevate 1.5 normal upper value ( see also ) . 3 . HLAA2 positive . 4 . The melanoma must express tyrosinase gene ( positive RTPCR frozen preimmune tumor sample ) ( see Appendix B ) . 5 . At least one measurable nonmeasurable tumor lesion ( see Section 8.1 ) . 6 . Expected survival least 3 month . 7 . Karnofsky performance scale ≥70 WHO performance status 0 1 ( see Appendix C ) . 8 . Vital laboratory parameter within normal range , except follow laboratory parameter , must within range specify : Lab Parameter Range Hemoglobin ≥ 10 g/dl ≥ 6,25 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Serum creatinin ≤ 2.0 mg/dl ≤ 177 μmol/l Serum bilirubin ≤ 2.0 mg/dl ≤ 34.2 μmol/l ASAT ALAT ≤ 2 x normal upper limit LDH ≤ 1.5 x normal upper limit . 9 . Viral serology : HIV ( human immunodeficiency virus ) : negative antibody . HBV ( hepatitis B virus ) : negative antigen ; antibody may positive . HCV ( hepatitis C virus ) : negative antibody . 10 . Age ≥ 18 year 11 . Able willing give valid write informed consent 1 . Previous treatment one regimen systemic chemotherapy , combine nonspecific immunotherapy interferon alpha interleukin . Chemoimmunotherapy radiotherapy must stop within precede 4 week ( 6 week nitrosoureas mitomycin C ) . 2 . Previous treatment vaccine know likely contain Tyrosinase.A2 epitope YMDGTMSQV . 3 . Clinically significant heart disease ( NYHA Class III IV ) i.e . NYHA class 3 congestive heart failure ; myocardial infarction within past six month ; unstable angina ; coronary angioplasty within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia . 4 . Active immunodeficiency autoimmune disease . Vitiligo exclusion criterion . 5 . Other serious acute chronic illness , e.g . active infection require antibiotic , bleed disorder , condition require concurrent medication allow study . 6 . Other malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ . 7 . Allergy kanamycin ( use preparation recombinant protein ) aminoglycoside antibiotic . 8 . Lack availability immunological clinical followup assessment . 9 . Participation clinical trial involve another investigational agent within 4 week prior enrollment . 10 . Pregnancy breastfeed . 11 . Women childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Safety</keyword>
	<keyword>Theravac vaccine</keyword>
	<keyword>HLA-A2 typing</keyword>
	<keyword>Tyrosinase.A2 gene expression</keyword>
</DOC>